Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis

Efe, Cumali; Al Taii, Haider; Ytting, Henriette; Aehling, Niklas; Bhanji, Rahima; Hagstrom, Hannes; PÜRNAK, TUĞRUL; Muratori, Luigi; Werner, Marten; Muratori, Paolo; Klintman, Daniel; Schiano, Thomas; Montano-Loza, Aldo; Berg, Thomas; Larsen, Fin; Alkhouri, Naim; Ozaslan, Ersan; Heneghan, Michael; Yoshida, Eric; Wahlin, Staffan

doi:10.1007/s10620-018-5011-x

Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis

Copy For Citation

Efe C., Al Taii H., Ytting H., Aehling N., Bhanji R. A., Hagstrom H., ...More

DIGESTIVE DISEASES AND SCIENCES, vol.63, no.5, pp.1348-1354, 2018 (SCI-Expanded)

Publication Type: Article / Article
Volume: 63 Issue: 5
Publication Date: 2018
Doi Number: 10.1007/s10620-018-5011-x
Journal Name: DIGESTIVE DISEASES AND SCIENCES
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1348-1354
Hacettepe University Affiliated: Yes

Abstract

We studied the efficacy and safety of mycophenolate mofetil (MMF) and tacrolimus as second-line therapy in pediatric patients with autoimmune hepatitis (AIH) who were intolerant or non-responders to standard therapy (corticosteroid and azathioprine).